Y. Xu

First name
Last name
Attar-Zadeh, D., Capstick, T., Leese, D., Arnetorp, S., Rapsomaniki, E., Da Costa, K. P., et al. (2023). Healthcare costs associated with short-acting β(2)-agonists in asthma: observational UK SABINA study. Bjgp Open. http://doi.org/10.3399/bjgpo.2023.0015
Whittaker, H., Nordon, C., Rubino, A., Morris, T., Xu, Y., de Nigris, E., et al. (2022). Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study. Thorax. http://doi.org/10.1136/thorax-2022-219039
Whittaker, H., Rubino, A., Mullerova, H., Morris, T., Varghese, P., Xu, Y., et al. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591
Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7